MedTrace Logo

CD123 Redirected Autologous T Cells for AML

NCT02623582 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2017-10-17

No results posted yet for this study

Summary

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.

Conditions

Interventions

BIOLOGICAL

Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes

Given IV

DRUG

Cyclophosphamide

Given IV

Sponsors & Collaborators

Principal Investigators

  • Saar Gill, MD, PhD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-08-26
Completion
2016-11-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02623582 on ClinicalTrials.gov